Bezinga: The Details Of The Acquisition Of Sapphire Biotech By Medical Marijuana Inc.’s AXIM Biotech

Medical Marijuana, Inc. MJNA 2.22% announced Thursday that its investment company, AXIM Biotechnologies Inc. AXIM, has entered a binding term sheet to acquire Sapphire Biotech, Inc., oncology research and development company. AXIM Biotechnologies and Sapphire plan to sign definitive documents for the transaction before the end of February.

Sapphire is working on the development of therapeutics for preventing cancer growth and metastasis. Its and AXIM scientists have been working on the invention of new synthetic cannabinoid-like molecules with the potential to help treat various illnesses, including cancer, as noted in a press release.

“AXIM has been a leader in cannabinoid research and development for many years now and we’re very excited to witness AXIM’s shared success with Sapphire Biotech to now become a leader in oncology research and development as well,” Medical Marijuana, Inc. CEO Dr. Stuart Titus said in a statement.

“Ninety percent of cancer deaths are caused by metastatic cancer and Sapphire has made great strides in discovering and analyzing cancer cells before they metastasize. AXIM will help accelerate these efforts significantly from the post pre-clinical phase to animal studies and eventually to human trials.”

Read on at

Cannabis Law Report Has Been Publishing Legal, Professional & Regulated
Cannabis News Daily Since 2016 – All For Free

We want to carry on providing the important cannabis sector
news for free for all our readers.

Costs are rising to produce Cannabis Law Report and we’d like to ask you,
our readers, for a small donation.

Primary Sponsor

Cannabis Banking - FinCann

New: Free USA Cannabis Case Law Search – New Cases Daily

Directory Categories

Karma Koala Podcast

Sponsor – aBizinaBox

Top Marijuana Blog
%d bloggers like this: